ATE64530T1 - Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten. - Google Patents

Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten.

Info

Publication number
ATE64530T1
ATE64530T1 AT84112946T AT84112946T ATE64530T1 AT E64530 T1 ATE64530 T1 AT E64530T1 AT 84112946 T AT84112946 T AT 84112946T AT 84112946 T AT84112946 T AT 84112946T AT E64530 T1 ATE64530 T1 AT E64530T1
Authority
AT
Austria
Prior art keywords
medication
manufacture
treatment
cardiovascular diseases
blood fat
Prior art date
Application number
AT84112946T
Other languages
German (de)
English (en)
Inventor
Ralph J Stolle
Lee R Dr Beck
Original Assignee
Stolle Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Res & Dev filed Critical Stolle Res & Dev
Application granted granted Critical
Publication of ATE64530T1 publication Critical patent/ATE64530T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT84112946T 1983-10-27 1984-10-26 Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten. ATE64530T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/546,162 US4636384A (en) 1982-06-03 1983-10-27 Method for treating disorders of the vascular and pulmonary systems
EP84112946A EP0143345B1 (en) 1983-10-27 1984-10-26 Use of hyperimmune milk for the manufacture of a medicament for the treatment of cardio-vascular diseases or for lowering lipid bloodstream levels

Publications (1)

Publication Number Publication Date
ATE64530T1 true ATE64530T1 (de) 1991-07-15

Family

ID=24179138

Family Applications (2)

Application Number Title Priority Date Filing Date
AT84112946T ATE64530T1 (de) 1983-10-27 1984-10-26 Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten.
AT90101230T ATE100325T1 (de) 1983-10-27 1990-01-22 Verwendung von milch zur herstellung einer hyperimmunmilchverbindung zur behandlung von erkrankungen des atmungssystems bei saeugetieren.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT90101230T ATE100325T1 (de) 1983-10-27 1990-01-22 Verwendung von milch zur herstellung einer hyperimmunmilchverbindung zur behandlung von erkrankungen des atmungssystems bei saeugetieren.

Country Status (8)

Country Link
US (1) US4636384A (https=)
EP (2) EP0380032B1 (https=)
AT (2) ATE64530T1 (https=)
CH (1) CH671517A5 (https=)
DE (2) DE3448494C2 (https=)
HK (1) HK1006004A1 (https=)
NL (1) NL8403248A (https=)
SE (1) SE466532B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932250A (en) * 1982-06-03 1999-08-03 Dcv, Inc. Anti-cholesterolemic egg, vaccine and method for production, and use
US5863561A (en) * 1982-06-03 1999-01-26 Stolle Research & Development Corporation Immune suppressive product
US5242691A (en) * 1982-06-03 1993-09-07 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US4879110A (en) * 1983-10-27 1989-11-07 Stolle Research And Development Corporation Antihypertensive hyperimmune milk, production, composition, and use
US4897265A (en) * 1983-10-27 1990-01-30 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US5130128A (en) * 1982-06-03 1992-07-14 Stolle Research & Development Corporation Use of honey as vaccine
US5753268A (en) * 1982-06-03 1998-05-19 Dcv Biologics, L.P. Anti-cholesterolemic egg, vaccine and method for production, and use
US5650175A (en) * 1982-06-03 1997-07-22 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5215746A (en) * 1982-06-03 1993-06-01 Stolle Research And Development Corporation Anti-cholesterolemic egg, vaccine and method for production, and use
US6054124A (en) * 1982-06-03 2000-04-25 Stolle Milk Biologics, Inc. Immune suppressive product
US5352462A (en) * 1982-06-03 1994-10-04 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5194255A (en) * 1982-06-03 1993-03-16 Stolle Research & Development Corporation Antihypertensive hyperimmune milk, production, composition, and use
US5849349A (en) * 1982-06-03 1998-12-15 Dcv, Inc. Anti-cholesterolemic egg, vaccine and method for production, and use
US4956349A (en) * 1983-10-27 1990-09-11 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US4994496A (en) * 1987-09-09 1991-02-19 Repasky Elizabeth A Use of milk globules as carriers for drugs
AU629559B2 (en) * 1988-08-04 1992-10-08 Thomas Julius Borody Oral antibody therapy for patients with lowered immune response and composition therefor
US5128127A (en) * 1989-02-08 1992-07-07 Stolle Research & Development Corp. Increased protein production in animals
EP0646017A1 (en) * 1990-07-05 1995-04-05 The Stolle Research And Development Corporation Immune suppressive product
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
EP0646014A4 (en) * 1992-06-16 1996-05-08 Stolle Res & Dev USING HYPERIMMUNE MILK TO INCREASE LIFETIME.
US6056978A (en) * 1992-06-16 2000-05-02 Stolle Milk Biologics, Inc. Use of hyperimmune milk to prevent suppression of T-lymphocyte production
JPH09500870A (ja) * 1993-05-26 1997-01-28 ストール・リサーチ・アンド・ディベロップメント・コーポレイション 抗‐コレステロール血症卵、ワクチンならびにその製法および使用
US5980953A (en) * 1994-10-03 1999-11-09 Stolle Milk Biologics, Inc. Anti-inflammatory factor, method of isolation, and use
FI955389A0 (fi) * 1995-11-09 1995-11-09 Antti Sakari Aaltonen Tandskyddande profylaktisk preparat och administreringsmedlen emot mellanoerpatogener
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US5980044A (en) * 1998-09-16 1999-11-09 Evans & Sutherland Computer Corp. Area of interest display system with image combining using error dithering
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
MXPA02012857A (es) * 2000-06-28 2004-07-30 Sericausa B V Uso de una formulacion elaborada de o que contiene al menos un suero de leche dismilado.
PL211753B1 (pl) * 2001-01-30 2012-06-29 Lauridsen Group Zastosowanie koncentratu antygenowo nie-specyficznych immunoglobulin pochodzących z krwi zwierząt i kompozycja farmaceutyczna zawierająca immunoglobuliny
US20030190314A1 (en) * 2001-01-30 2003-10-09 The Lauridsen Group Methods and compositions of treatment for modulating the immune system of animals
MXPA03006818A (es) * 2001-01-30 2004-10-15 Lauridsen Group Inc Metodos y composiciones para modular el sistema inmune de animales.
US6770280B1 (en) 2001-11-15 2004-08-03 Humanetics Corporation Treatment of menorrhagia, hypermenorrhea, dysmenorrhea and menstrual migraines by the administration of an antibacterial milk product
US20030223985A1 (en) * 2002-05-29 2003-12-04 The Lauridsen Group. Incorporated Globulin protein to lower cholesterol in humans
US20060013890A1 (en) * 2004-06-24 2006-01-19 Green Shawn J Dairy-derived anticholesterol immunoglobulin to lower dietary cholesterol in humans
US20070087002A1 (en) * 2005-10-14 2007-04-19 Green Shawn J Anticholesterol immunoglobulin to treat lipid raft diseases
CN101617354A (zh) 2006-12-12 2009-12-30 埃文斯和萨瑟兰计算机公司 用于校准单个调制器投影仪中的rgb光的系统和方法
US8358317B2 (en) 2008-05-23 2013-01-22 Evans & Sutherland Computer Corporation System and method for displaying a planar image on a curved surface
US8702248B1 (en) 2008-06-11 2014-04-22 Evans & Sutherland Computer Corporation Projection method for reducing interpixel gaps on a viewing surface
US8077378B1 (en) 2008-11-12 2011-12-13 Evans & Sutherland Computer Corporation Calibration system and method for light modulation device
US9641826B1 (en) 2011-10-06 2017-05-02 Evans & Sutherland Computer Corporation System and method for displaying distant 3-D stereo on a dome surface

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128230A (en) * 1961-04-04 1964-04-07 Sunbury Milk Products Co Milk having antibodies therein and process for producing same
US3376198A (en) * 1965-07-21 1968-04-02 Collins Products Inc Method of producing antibodies in milk
US3911108A (en) * 1973-02-14 1975-10-07 Diamond Shamrock Corp Process of producing bovine milk products containing specific antibodies
US4324782A (en) * 1974-01-28 1982-04-13 Beck Lee R Dental caries inhibiting product of immunized cow's milk having antibodies specific to killed Streptococcus mutans cells
GB1505513A (en) * 1975-05-23 1978-03-30 Stolle Res & Dev Dental caries inhibiting product
SE448344B (sv) * 1978-02-06 1987-02-16 Stolle Res & Dev Antikropp for behandling av reumatoid artrit samt sett att framstella denna
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
US4377569A (en) * 1980-01-21 1983-03-22 Plymate Robert R Method of treating animals to resist infectious diseases
ATE16349T1 (de) * 1981-04-28 1985-11-15 Stolle Res & Dev Verfahren zur herstellung einer entzuendungshemmenden rindermilch.

Also Published As

Publication number Publication date
DE3448494C2 (https=) 1993-09-23
ATE100325T1 (de) 1994-02-15
CH671517A5 (https=) 1989-09-15
DE3439345A1 (de) 1986-04-24
EP0380032A1 (en) 1990-08-01
DE3439345C2 (de) 1993-10-14
EP0143345A3 (en) 1987-09-30
SE8405351L (sv) 1985-04-28
SE8405351D0 (sv) 1984-10-26
EP0143345B1 (en) 1991-06-19
NL8403248A (nl) 1985-05-17
EP0380032B1 (en) 1994-01-19
SE466532B (sv) 1992-03-02
US4636384A (en) 1987-01-13
EP0143345A2 (en) 1985-06-05
HK1006004A1 (en) 1999-02-05

Similar Documents

Publication Publication Date Title
ATE64530T1 (de) Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten.
DE69012591D1 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
Danaraj et al. Primary arteritis of abdominal aorta in children causing bilateral stenosis of renal arteries and hypertension
Wilgis Evaluation and treatment of chronic digital ischemia
Carey et al. Homocystinuria: I. A clinical and pathological study of nine subjects in six families
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE144142T1 (de) Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
EP0376251A3 (en) An anticoagulant substance obtained from urine
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE77751T1 (de) Mittel zur behandlung von knochenkrankheiten.
DE69021257D1 (de) Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL.
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
Schmiegelow The Surgical Treatment of Chronic Cicatricial Stenosis of the Larynx:(Semon Lecture 1937)
Pepper et al. A CASE OF FATAL HEMOLYSIS FOLLOWING DIRECT TRANSFUSION OF BLOOD BY ARTERIOVENOUS ANASTOMOSIS.
Bowman The Collected papers of Sir W. Bowman v. 2
Rocchi et al. Effect of vitamin A acetate on mutagenesis induced by ultraviolet light in human cells
Kelly Brain from a Patient who presented Nystagmoid Movements in the Pharynx and Larynx
Christian THE MECHANISM OF EDEMA: IN RELATION TO THE CLINICAL CLASSIFICATION OF BRIGHT'S LISEASE (NEPHRITIS)
DE3850691D1 (de) Verwendung von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung von Knochenverletzungen.
SMITH Spontaneous Gangrene of the Extremities
Pastore et al. 793bis—Interpretation of low-frequency pulsating magnetic field effects on patients affected by peripheral arteriopathy
Oh et al. Malignant schwannoma associated with von Recklinghausen's disease: Report of 1 case
Johnson A Lecture on Haemoptysis: Its Causes, Results, and Treatment

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee